Skip to main content
TARS
NASDAQ Life Sciences

Tarsus to Acquire Alkeus for $450M Upfront, Adding Phase 3 Stargardt Asset

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$58.5
Mkt Cap
$2.637B
52W Low
$40.55
52W High
$85.25
52W Position info
44% above low
Off High info
31% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).

Summary

Tarsus Pharmaceuticals will acquire Alkeus Pharmaceuticals for $450 million upfront ($270M cash, $180M stock) plus milestones, gaining a Phase 3 Stargardt disease therapy. The deal expands Tarsus's retina pipeline and is priced at a premium to market.

Updates

  1. · SEC 8-K — The 8-K details 2,098,519 shares at $56.00 and 133,625 pre-funded warrants at $55.9999, with closing expected August 7, 2026.


Key Events · M&A and Partnerships · TARS

  • Acquisition of Alkeus Pharmaceuticals

    Tarsus will acquire Alkeus for $270M cash and $180M in stock upfront, plus up to $350M in regulatory and commercial milestones, and low-single-digit royalties on gildeuretinol sales.

  • Stock Consideration Priced at Premium

    The $180M stock component is valued at $61.38 per share, a 5% premium to Tarsus's current $58.50 price, reflecting seller confidence in the deal.

  • Adds Phase 3 Stargardt Disease Asset

    Gildeuretinol (ALK-001) is an oral therapy for Stargardt disease, a rare inherited retinal disease with no FDA-approved treatment. Phase 3 NORTHSTAR trial data expected in the second half of 2029.

  • Lock-Up and Registration Rights

    Alkeus stockholders receiving upfront stock are subject to a 2-month lock-up, with additional volume-based selling limits for 3 months thereafter. Tarsus will file a resale shelf registration for the shares.


Analysis · TARS · Life Sciences

Tarsus is buying Alkeus Pharmaceuticals for $270 million in cash and $180 million in stock, with up to $350 million more in milestones. The deal brings gildeuretinol, a Phase 3 oral therapy for Stargardt disease — a rare, blinding retinal condition with no approved treatment. The stock portion is priced at $61.38, a premium to today's $58.50, signaling seller confidence. This follows last month's iRenix acquisition and builds a retina franchise. The upfront cost is significant but manageable given Tarsus's $2.6 billion market cap and recent XDEMVY sales momentum. Key risk: Phase 3 data not until 2029, so the payoff is years away.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARS was trading at $58.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $81.22 info
Change: +$7.22 (+10%) info
Market Cap: $3.958B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $81.22 info
Change: +$9.98 (+14%) info
Market Cap: $3.958B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $81.22 info
Change: +$10.40 (+15%) info
Market Cap: $3.958B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $81.22 info
Change: +$0.100 (+0.12%) info
Market Cap: $3.958B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $81.22 info
Change: +$22.95 (+39%) info
Market Cap: $3.958B info